Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.00 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 135.20K shares, a 68.95% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 867.81K shares, a 81.15% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -4.97M shares, a 6744.34% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 268.80K shares, a 17.24% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 339.11K shares, a 95.51% decline from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 7.55M shares, a 75.83% increase from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.29M shares, a 59.46% increase from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.69M shares, a 24.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 135.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 1.00M shares 10-Q · filed 2026-08-05 | -3.97M shares derived: sum of 3 quarters · filed 2026-08-05 | -3.70M shares derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | 867.81K shares 10-Q · filed 2026-05-13 | -4.10M shares derived: sum of 2 quarters · filed 2026-05-13 | -3.83M shares derived: sum of 3 quarters · filed 2026-05-13 | -3.40M shares derived: sum of 4 quarters · filed 2026-05-13 | |
| 2025-12-31 | -4.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -4.70M shares derived: sum of 2 quarters · filed 2026-03-12 | -4.27M shares derived: sum of 3 quarters · filed 2026-03-12 | 339.11K shares 10-K · filed 2026-03-12 | |
| 2025-09-30 | 268.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 704.20K shares derived: sum of 2 quarters · filed 2025-11-05 | 5.31M shares 10-Q · filed 2025-11-05 | 5.38M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 435.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 5.04M shares 10-Q · filed 2025-08-07 | 5.12M shares derived: sum of 3 quarters · filed 2025-08-07 | 5.44M shares derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | 4.60M shares 10-Q · filed 2025-05-06 | 4.68M shares derived: sum of 2 quarters · filed 2025-05-06 | 5.00M shares derived: sum of 3 quarters · filed 2025-05-06 | 8.59M shares derived: sum of 4 quarters · filed 2025-05-06 | |
| 2024-12-31 | 74.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 399.60K shares derived: sum of 2 quarters · filed 2025-03-06 | 3.98M shares derived: sum of 3 quarters · filed 2025-03-06 | 7.55M shares 10-K · filed 2025-03-06 | |
| 2024-09-30 | 324.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 3.91M shares derived: sum of 2 quarters · filed 2024-11-06 | 7.47M shares 10-Q · filed 2024-11-06 | 7.60M shares derived: sum of 4 quarters · filed 2024-11-06 | |
| 2024-06-30 | 3.58M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 7.15M shares 10-Q · filed 2024-08-13 | 7.28M shares derived: sum of 3 quarters · filed 2024-08-13 | 8.88M shares derived: sum of 4 quarters · filed 2024-08-13 | |
| 2024-03-31 | 3.57M shares 10-Q · filed 2024-05-14 | 3.69M shares derived: sum of 2 quarters · filed 2024-05-14 | 5.30M shares derived: sum of 3 quarters · filed 2024-05-14 | 5.74M shares derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | 126.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 1.73M shares derived: sum of 2 quarters · filed 2024-03-19 | 2.18M shares derived: sum of 3 quarters · filed 2024-03-19 | 4.29M shares 10-K · filed 2024-03-19 | |
| 2023-09-30 | 1.61M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 2.05M shares derived: sum of 2 quarters · filed 2023-11-08 | 4.17M shares 10-Q · filed 2023-11-08 | 4.64M shares derived: sum of 4 quarters · filed 2023-11-08 | |
| 2023-06-30 | 443.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 2.56M shares 10-Q · filed 2023-08-09 | 3.03M shares derived: sum of 3 quarters · filed 2023-08-09 | 3.26M shares derived: sum of 4 quarters · filed 2023-08-09 | |
| 2023-03-31 | 2.12M shares 10-Q · filed 2023-05-09 | 2.59M shares derived: sum of 2 quarters · filed 2023-05-09 | 2.82M shares derived: sum of 3 quarters · filed 2023-05-09 | 3.25M shares derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-12-31 | 473.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 700.00K shares derived: sum of 2 quarters · filed 2023-03-15 | 1.14M shares derived: sum of 3 quarters · filed 2023-03-15 | 2.69M shares 10-K · filed 2023-03-15 | |
| 2022-09-30 | 226.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 664.30K shares derived: sum of 2 quarters · filed 2022-11-08 | 2.22M shares 10-Q · filed 2022-11-08 | 2.43M shares derived: sum of 4 quarters · filed 2022-11-08 | |
| 2022-06-30 | 437.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 1.99M shares 10-Q · filed 2022-08-10 | 2.20M shares derived: sum of 3 quarters · filed 2022-08-10 | 2.24M shares derived: sum of 4 quarters · filed 2022-08-10 | |
| 2022-03-31 | 1.55M shares 10-Q · filed 2022-05-12 | 1.76M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.80M shares derived: sum of 3 quarters · filed 2022-05-12 | 2.01M shares derived: sum of 4 quarters · filed 2022-05-12 | |
| 2021-12-31 | 207.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 250.00K shares derived: sum of 2 quarters · filed 2022-03-15 | 458.34K shares derived: sum of 3 quarters · filed 2022-03-15 | 2.16M shares 10-K · filed 2022-03-15 | |
| 2021-10-31 | 560.00K shares 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | 43.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 251.34K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.95M shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 208.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.91M shares 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 1.70M shares 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | 2.28M shares 10-K · filed 2021-03-12 | ||||
| 2019-12-31 | 1.12M shares 10-K · filed 2021-03-12 | ||||
| 2018-12-31 | 210.45K shares 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |